Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology.

Predictors of Catastrophic Adverse Outcomes in Children With Pulmonary Hypertension Undergoing Cardiac Catheterization: A Multi-Institutional Analysis From the Pediatric Health Information Systems Database. J Am Coll Cardiol (2015) 3.09

Association of the metabolic syndrome with pulmonary venous hypertension. Chest (2009) 2.75

Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol (2009) 2.57

Noninvasive assessment of murine pulmonary arterial pressure: validation and application to models of pulmonary hypertension. Circ Cardiovasc Imaging (2009) 2.05

Increased tricuspid regurgitant jet velocity by Doppler echocardiography in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. J Clin Oncol (2013) 2.03

Risks of contraception and pregnancy in heart disease. Heart (2006) 1.60

Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort. Heart (2012) 1.39

Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol (2008) 1.38

Fetal growth restriction and pulmonary hypertension in premature infants with bronchopulmonary dysplasia. J Perinatol (2013) 1.36

Elevated plasma endothelin-1 and pulmonary arterial pressure in children exposed to air pollution. Environ Health Perspect (2007) 1.29

Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study. Rheumatology (Oxford) (2009) 1.18

Pulmonary hypertension: diagnosis and management. Mayo Clin Proc (2009) 1.18

Exercise stress echocardiography for the study of the pulmonary circulation. Eur Respir J (2009) 1.15

Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J (2008) 1.10

Review of bosentan in the management of pulmonary arterial hypertension. Vasc Health Risk Manag (2007) 1.09

The adult patient with eisenmenger syndrome: a medical update after dana point part I: epidemiology, clinical aspects and diagnostic options. Curr Cardiol Rev (2010) 1.06

Vasoreactivity to inhaled nitric oxide with oxygen predicts long-term survival in pulmonary arterial hypertension. Pulm Circ (2011) 1.05

Scleroderma lung disease. Eur Respir Rev (2013) 1.04

Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. Can J Cardiol (2009) 1.04

Repair of congenital heart disease with associated pulmonary hypertension in children: what are the minimal investigative procedures? Consensus statement from the Congenital Heart Disease and Pediatric Task Forces, Pulmonary Vascular Research Institute (PVRI). Pulm Circ (2014) 1.02

Right ventricular dysfunction is associated with chronic kidney disease and predicts survival in patients with chronic systolic heart failure. Eur J Heart Fail (2012) 1.00

Evaluation of elevated mean pulmonary arterial pressure based on magnetic resonance 4D velocity mapping: comparison of visualization techniques. PLoS One (2013) 0.97

ACE2, a promising therapeutic target for pulmonary hypertension. Curr Opin Pharmacol (2011) 0.97

A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs (2006) 0.94

Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. Vasc Health Risk Manag (2009) 0.94

Epoprostenol treatment in children with severe pulmonary hypertension. Heart (2006) 0.93

Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol (2007) 0.91

Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan. Ther Clin Risk Manag (2010) 0.89

Pathogenesis of HIV-associated pulmonary hypertension: potential role of HIV-1 Nef. Proc Am Thorac Soc (2011) 0.89

Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Can Respir J (2008) 0.89

Overview of current therapeutic approaches for pulmonary hypertension. Pulm Circ (2011) 0.89

Clinical features and independent predictors of pulmonary arterial hypertension in systemic lupus erythematosus. Rheumatol Int (2011) 0.89

Prostacyclin therapy for pulmonary arterial hypertension. Tex Heart Inst J (2010) 0.88

Risk factors for hemoptysis in idiopathic and hereditary pulmonary arterial hypertension. PLoS One (2013) 0.87

Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability, clinical, and haemodynamic effect. Heart (2006) 0.86

Arterial pulmonary hypertension in noncardiac intensive care unit. Vasc Health Risk Manag (2008) 0.86

Continuous intravenous iloprost to revert treatment failure of first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Clin Res Cardiol (2007) 0.86

Echocardiographic assessment of estimated right atrial pressure and size predicts mortality in pulmonary arterial hypertension. Chest (2015) 0.85

Prevalence of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review of the literature. Clin Rheumatol (2013) 0.85

Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease. Heart (2007) 0.85

Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc Health Risk Manag (2009) 0.85

Time-domain analysis of heart sound intensity in children with and without pulmonary artery hypertension: a pilot study using a digital stethoscope. Pulm Circ (2014) 0.84

Functional class and targeted therapy are related to the survival in patients with pulmonary arterial hypertension. Yonsei Med J (2014) 0.84

The short- and medium-term results of transcatheter closure of atrial septal defect with severe pulmonary arterial hypertension. Heart Vessels (2011) 0.84

Treprostinil for pulmonary hypertension. Vasc Health Risk Manag (2008) 0.84

Noninvasive assessment of acute cardiopulmonary effects of an oral single dose of sildenafil in patients with idiopathic pulmonary hypertension. Heart Vessels (2010) 0.83

Beneficial and adverse effects of bosentan treatment in korean patients with pulmonary artery hypertension. Korean Circ J (2009) 0.83

The management of pulmonary hypertension in children. Arch Dis Child (2008) 0.83

The usefulness of contrast during exercise echocardiography for the assessment of systolic pulmonary pressure. Cardiovasc Ultrasound (2008) 0.83

Non-invasive diagnostic and functional evaluation of cardiac involvement in patients with systemic sclerosis. Clin Rheumatol (2008) 0.82

Optimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment course. Ther Clin Risk Manag (2014) 0.82

Perivascular T-cell infiltration leads to sustained pulmonary artery remodeling after endothelial cell damage. Am J Respir Cell Mol Biol (2010) 0.82

Review of Movahed's sign (D shaped left ventricle seen on gated SPECT) suggestive of right ventricular overload. Int J Cardiovasc Imaging (2010) 0.82

Impact of calcium-channel blockers on right heart function in a controlled model of chronic pulmonary hypertension. Eur J Anaesthesiol (2009) 0.82

Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients. Health Qual Life Outcomes (2013) 0.82

Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist. Eur J Clin Pharmacol (2016) 0.82

Stress Doppler echocardiography for early detection of systemic sclerosis-associated pulmonary arterial hypertension. Arthritis Res Ther (2015) 0.81

Estimated right ventricular systolic pressure during exercise stress echocardiography in patients with suspected coronary artery disease. Can J Cardiol (2010) 0.81

Treprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes. Br J Pharmacol (2007) 0.81

The interaction of endothelin-1 and TGF-β1 mediates vascular cell remodeling. PLoS One (2013) 0.81

Treatment of pediatric pulmonary hypertension. Vasc Health Risk Manag (2009) 0.80

Noninvasive assessment of elevated pulmonary vascular resistance in children with pulmonary hypertension secondary to congenital heart disease: A comparative study between five different Doppler indices. J Saudi Heart Assoc (2012) 0.80

Variable prevalence of pulmonary hypertension in patients with advanced interstitial pneumonia. J Heart Lung Transplant (2010) 0.79

Clinical practice: pulmonary hypertension in children. Eur J Pediatr (2009) 0.79

Platelets in pulmonary hypertension: a causative role or a simple association? Iran J Pediatr (2012) 0.79

The importance of trabecular hypertrophy in right ventricular adaptation to chronic pressure overload. Int J Cardiovasc Imaging (2013) 0.79

[Interdisciplinary point of contact between rheumatology and pneumology]. Z Rheumatol (2008) 0.79

Assessment of perfusion pattern and extent of perfusion defect on dual-energy CT angiography: correlations between the causes of pulmonary hypertension and vascular parameters. Korean J Radiol (2014) 0.78

Improvement in right ventricular function during reversibility testing in pulmonary arterial hypertension: a case report. Cardiovasc Ultrasound (2009) 0.78

Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension. J Cardiovasc Pharmacol (2015) 0.78

Pulmonary hypertension in patients with idiopathic pulmonary fibrosis - the predictive value of exercise capacity and gas exchange efficiency. PLoS One (2013) 0.78

The Role of Hyperglycemia and Insulin Resistance in the Development and Progression of Pulmonary Arterial Hypertension. J Diabetes Res (2016) 0.77

Tadalafil: the evidence for its clinical potential in the treatment of pulmonary arterial hypertension. Core Evid (2008) 0.77

Pathophysiological adaptations to walking and cycling in primary pulmonary hypertension. Eur J Appl Physiol (2007) 0.77

Use of inhaled iloprost in an infant with bronchopulmonary dysplasia and pulmonary artery hypertension. Korean Circ J (2009) 0.77

High-sensitive Troponin T increase after exercise in patients with pulmonary arterial hypertension. BMC Pulm Med (2013) 0.77

[Pulmonary arterial hypertension in collagenoses: clinical features, epidemiology, pathogenesis, diagnosis and treatment]. Z Rheumatol (2006) 0.76

Pulmonary arterial hypertension in a patient with β-thalassemia intermedia and reversal with infusion epoprostenol then transition to oral calcium channel blocker therapy: review of literature. Pulm Circ (2014) 0.76

Survival in an incident cohort of patients with pulmonary arterial hypertension in Denmark. Pulm Circ (2015) 0.76

Significant increase in factual knowledge with web-assisted problem-based learning as part of an undergraduate cardio-respiratory curriculum. Adv Health Sci Educ Theory Pract (2009) 0.76

[Diagnosis and therapy of chronic pulmonary hypertension]. Clin Res Cardiol (2007) 0.75

Erythrocyte glutathione transferase: a non-antibody biomarker for systemic sclerosis, which correlates with severity and activity of the disease. Cell Death Dis (2013) 0.75

Long term survival of patients with raised pulmonary arterial systolic pressure utilizing echocardiography-a five-year prospective study. J Geriatr Cardiol (2012) 0.75

N-terminal probrain natriuretic peptide as a biochemical marker in the evaluation of bosentan treatment in systemic-sclerosis-related pulmonary arterial hypertension. Clin Rheumatol (2008) 0.75

Clinical characteristics and risk factors of pulmonary hypertension associated with chronic respiratory diseases: a retrospective study. J Thorac Dis (2016) 0.75

Complete therapeutical approach in pulmonary arterial hypertension: from vasodilators to lung transplantation - case report. Maedica (Buchar) (2014) 0.75

An unexpected diagnosis in a dyspnoeic patient with primary Sjogren syndrome. BMJ Case Rep (2013) 0.75

Treatment options for transposition of the great arteries with ventricular septal defect complicated by pulmonary vascular obstructive disease. J Saudi Heart Assoc (2009) 0.75

Is early diagnosis of pulmonary arterial hypertension possible in inflammatory rheumatic diseases? Experience from a single center in Turkey. Eur J Rheumatol (2015) 0.75

Effect of dual pulmonary vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease: a retrospective analysis. Open Heart (2016) 0.75

Drugs for pulmonary arterial hypertension: a systematic review of the clinical-effectiveness of combination therapy. CADTH Technol Overv (2010) 0.75

Stepwise Approach Using Combined Management in Patients with Congenital Heart Disease and Borderline Pulmonary Vascular Disease. Korean Circ J (2015) 0.75

Integrated care and optimal management of pulmonary arterial hypertension. J Multidiscip Healthc (2009) 0.75

Diagnosis of pulmonary hypertension from magnetic resonance imaging-based computational models and decision tree analysis. Pulm Circ (2016) 0.75

Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension. PLoS One (2016) 0.75

Identification of myocardial damage in systemic sclerosis: a nuclear cardiology approach. Int J Rheumatol (2010) 0.75

Right-to-left shunt with hypoxemia in pulmonary hypertension. BMC Cardiovasc Disord (2009) 0.75

Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: a qualitative systematic review. Can J Cardiol (2009) 0.75

Pulmonary hypertension-"state of the art" management in 2012. Indian Heart J (2012) 0.75

Clinical and laboratory profiles of 136 systemic sclerosis patients with and without echocardiographically detected pulmonary hypertension. Z Rheumatol (2015) 0.75

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet (2004) 42.12

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09

Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03

Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr (2009) 14.63

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J (2009) 14.06

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73

Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J (2008) 12.31

Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J (2009) 11.90

Universal definition of myocardial infarction. Circulation (2007) 11.69

ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 11.49

Bosentan therapy for pulmonary arterial hypertension. N Engl J Med (2002) 11.18

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail (2012) 10.38

How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J (2007) 10.38

Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J (2007) 9.80

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54

2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43

Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med (2014) 9.33

Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med (2005) 9.27

Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93

Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61

Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59

Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49

Third universal definition of myocardial infarction. Circulation (2012) 8.47

Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J (2009) 8.25

Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol (2009) 7.94

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 7.75

Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr (2009) 7.69

Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell (2004) 7.45

A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32

A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med (2011) 7.21

Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J (2005) 6.93

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J (2007) 6.51

2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J (2014) 6.32

2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J (2013) 6.17

ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol (2006) 6.11

European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10

Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA (2007) 6.06

ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation (2006) 5.95

European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J (2007) 5.92

Clinical classification of pulmonary hypertension. J Am Coll Cardiol (2004) 5.87

ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol (2006) 5.81

Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J (2006) 5.79

Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74

Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med (2013) 5.60

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation (2009) 5.49

Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol (2009) 5.31